NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

Home・Akciju saraksts・Roche Holding AG

Roche Holding AG

Slēgts

SektorsVeselības aprūpe

325.6 0.74

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

325.4

Max

326.6

Galvenie mērījumi
By Trading Economics
Ienākumi	1.8B 5.5B
Pārdošana	15B 31B
P/E Sektora vidējais	20.461 67.147
Dividenžu ienesīgums	2.97
Peļņas marža	17.892
Darbinieki	103,249
EBITDA	5.1B 12B

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	2.97% 2.36%

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-28B 261B
Iepriekšējā atvēršanas cena	324.86
Iepriekšējā slēgšanas cena	325.6

Ziņu noskaņojums

By Acuity

14%

86%

24 / 347 Rangs Healthcare

Roche Holding AG Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. apr. 07:46 UTC

Peļņas

Roche Backs Full-Year View as Quarterly Sales Rise -- Update

2026. g. 23. apr. 05:40 UTC

Peļņas

Roche Backs Full-Year View as Quarterly Sales Rise

2026. g. 9. marts 16:43 UTC

Galvenie tirgus virzītāji

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update

2026. g. 9. marts 15:44 UTC

Galvenie tirgus virzītāji

Correction to Roche Shares Article

2026. g. 9. marts 09:51 UTC

Galvenie tirgus virzītāji

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study

2026. g. 6. marts 09:24 UTC

Galvenie tirgus virzītāji

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

2026. g. 29. janv. 10:07 UTC

Peļņas

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

2026. g. 29. janv. 07:07 UTC

Peļņas

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

2026. g. 27. apr. 09:54 UTC

Tirgus saruna

Roche's Vabysmo U.S. Recovery Will Be Key -- Market Talk

2026. g. 23. apr. 08:10 UTC

Tirgus saruna

Peļņas

Roche Reports In Line Sales Figures -- Market Talk

2026. g. 23. apr. 05:04 UTC

Peļņas

Roche Backs 2026 View

2026. g. 23. apr. 05:04 UTC

Peļņas

Roche Diagnostics Division 1Q Sales Up at 3% Constant Currency

2026. g. 23. apr. 05:03 UTC

Peļņas

Roche Pharmaceutical Division 1Q Sales Up 7% at Constant Currency

2026. g. 23. apr. 05:02 UTC

Peļņas

Roche 1Q Group Sales Up 6% at Constant Currency

2026. g. 23. apr. 05:02 UTC

Peļņas

Analysts Saw Roche 1Q Sales at CHF14.73B

2026. g. 23. apr. 05:01 UTC

Peļņas

Roche 1Q Sales CHF14.72B

2026. g. 10. apr. 11:28 UTC

Tirgus saruna

Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk

2026. g. 10. apr. 11:17 UTC

Tirgus saruna

Roche to Face Significant Currency Headwinds -- Market Talk

2026. g. 11. marts 10:57 UTC

Tirgus saruna

Roche Sees Mixed Fortunes in Immunology, Oncology -- Market Talk

2026. g. 9. marts 09:43 UTC

Karstas akcijas

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

2026. g. 6. marts 07:22 UTC

Tirgus saruna

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

2026. g. 3. marts 07:22 UTC

Tirgus saruna

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2026. g. 2. marts 14:21 UTC

Tirgus saruna

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

2026. g. 29. janv. 11:40 UTC

Tirgus saruna

Peļņas

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

2026. g. 29. janv. 06:05 UTC

Peļņas

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

2026. g. 29. janv. 06:04 UTC

Peļņas

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

2026. g. 29. janv. 06:03 UTC

Peļņas

Roche Issues 2026 View

2026. g. 29. janv. 06:02 UTC

Peļņas

Analysts Saw 2025 Core EPS at CHF19.70

2026. g. 29. janv. 06:02 UTC

Peļņas

Roche: 2025 Core EPS CHF19.46

2026. g. 29. janv. 06:01 UTC

Peļņas

Analysts Had Seen 2025 Sales At CHF61.47B

Salīdzinājums

Cenas izmaiņa

Roche Holding AG Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Roche Holding AG — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

24 / 347 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.